Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.48 |
| ▸ | DRD4 | P21917 | 3/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.48 |
| ▸ | HTR2A | P28223 | 8/20 | 0.47 |
| ▸ | HTR7 | P34969 | 7/20 | 0.47 |
| ▸ | HTR6 | P50406 | 3/20 | 0.46 |
| ▸ | HTR1A | P08908 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6405448 | 0.95 | HTR7 (0.51) | DRD2DRD4HTR2AHTR7HTR6 | |
| SCHEMBL6404206 | 0.94 | HTR2A (0.48) | DRD2DRD4SIGMAR1HTR2AHTR7 | |
| SCHEMBL6404377 | 0.89 | HTR2A (0.49) | DRD2DRD4HTR2AHTR7HTR6 | |
| SCHEMBL6405450 | 0.86 | HTR7 (0.48) | DRD2DRD4SIGMAR1HTR2AHTR7 | |
| SCHEMBL6406964 | 0.85 | HTR2A (0.48) | DRD2HTR2AHTR7HTR6HTR1A | |
| SCHEMBL6399207 | 0.84 | HTR2A (0.50) | DRD2DRD4SIGMAR1HTR2AHTR7 | |
| SCHEMBL5738682 | 0.84 | SIGMAR1 (0.38) | DRD2SIGMAR1HTR2AHTR7HTR1A | |
| SCHEMBL6400717 | 0.81 | HTR2A (0.48) | DRD2DRD4SIGMAR1HTR2AHTR7 | |
| SCHEMBL6401030 | 0.81 | HTR7 (0.52) | DRD2DRD4HTR2AHTR7HTR6 | |
| SCHEMBL6399597 | 0.81 | HTR1A (0.56) | DRD2HTR2AHTR7HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050282819-A1 | Heterocyclic substituted indane derivatives and related compounds for the treatment of schizophrenia | GRAHAM JAMES M | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282819-A1 | Heterocyclic substituted indane derivatives and related compounds for the treatment of schizophrenia | CHRM1, CHRM2, CHRM5 | DRD2 9/4885DRD4 48/4885SIGMAR1 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.